Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07624071 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate ALN-6222 in Participants With Obesity

Name: A Study to Evaluate ALN-6222 in Participants With Obesity — clinical trial record (NCT07624071)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorAlnylam Pharmaceuticals

Started2026-06-04

View on ClinicalTrials.gov ↗

Amendment history

2026-09-02

3 amendments v2-v4

3 re-verifications since 2026-07-22, no change to tracked fields

2026-06-25

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-06-03→confirmed 2026-06-04

Study sitesdetails revised at 1 of 1 site

2026-05-29

Original filing

Alnylam Pharmaceuticals

31 trials monitored

See 5 trials at risk

Obesity

3,523 trials monitored

See 133 trials at risk

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Trial Details

NCT Number	NCT07624071
Lead Sponsor	Alnylam Pharmaceuticals
Conditions	Obesity
Enrollment	88 participants
Start Date	2026-06-04
Primary Completion	2027-12-14 (estimated)
Study Completion	2027-12-14 (estimated)
Updated on ClinicalTrials.gov	2026-09-03